Werner Seeger Selected Research

tolafentrine

3/2011	cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases.
11/2005	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
4/2004	Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Werner Seeger Research Topics

Disease

112	Pulmonary Hypertension 01/2022 - 01/2002
82	Hypoxia (Hypoxemia) 01/2022 - 01/2002
64	Pulmonary Arterial Hypertension 01/2022 - 04/2002
41	Neoplasms (Cancer) 02/2022 - 03/2004
39	Fibrosis (Cirrhosis) 01/2022 - 09/2002
37	Vascular Remodeling 01/2022 - 04/2004
26	Idiopathic Pulmonary Fibrosis 11/2022 - 12/2007
22	Inflammation (Inflammations) 02/2022 - 06/2002
22	Lung Neoplasms (Lung Cancer) 01/2022 - 09/2006
22	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 06/2020 - 12/2003
18	Familial Primary Pulmonary Hypertension 01/2022 - 05/2002
18	Lung Injury 11/2019 - 01/2004
17	Lung Diseases (Lung Disease) 01/2022 - 09/2004
17	Pneumonia (Pneumonitis) 01/2019 - 06/2002
16	Pulmonary Fibrosis (Fibrosing Alveolitis) 03/2022 - 12/2003
16	Acute Lung Injury 11/2017 - 02/2007
15	Hyperoxia 01/2022 - 02/2007
15	Edema (Dropsy) 12/2021 - 03/2003
15	Infections 10/2021 - 03/2003
14	Bronchopulmonary Dysplasia 01/2022 - 02/2007
13	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 10/2008
12	Cardiomegaly (Heart Hypertrophy) 01/2021 - 01/2004
11	Emphysema 01/2022 - 10/2011
11	Heart Failure 01/2021 - 01/2015
11	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2019 - 07/2002
10	Neoplasm Metastasis (Metastasis) 02/2022 - 03/2010
10	Right Ventricular Hypertrophy 01/2021 - 01/2010
10	Hypertrophy 01/2021 - 08/2007
10	Sepsis (Septicemia) 07/2014 - 06/2002
8	Hypercapnia 12/2021 - 02/2008
8	Critical Illness (Critically Ill) 06/2020 - 03/2006
7	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2002
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 10/2009
6	Body Weight (Weight, Body) 12/2018 - 12/2003
5	COVID-19 06/2022 - 01/2020
5	Hypertension (High Blood Pressure) 12/2020 - 03/2006
5	Dyspnea (Shortness of Breath) 11/2020 - 08/2002
5	Hyperplasia 11/2014 - 05/2008
5	Ischemia 03/2009 - 03/2003

Drug/Important Bio-Agent (IBA)

39	Proteins (Proteins, Gene)FDA Link 02/2022 - 02/2004
28	MonocrotalineIBA 02/2021 - 01/2004
25	Oxygen (Dioxygen)IBA 01/2022 - 01/2002
24	Bleomycin (Blenoxane)FDA LinkGeneric 03/2022 - 12/2003
23	Iloprost (Ventavis)FDA Link 01/2022 - 01/2002
21	Sildenafil Citrate (Viagra)FDA Link 01/2018 - 04/2002
20	CytokinesIBA 01/2022 - 06/2002
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2008
14	CollagenIBA 01/2020 - 12/2003
14	Surface-Active Agents (Surfactants)IBA 01/2017 - 01/2004
13	LipidsIBA 06/2020 - 05/2002
13	ProstaglandinsIBA 12/2018 - 06/2002
12	Transcription Factors (Transcription Factor)IBA 01/2022 - 10/2002
12	Pharmaceutical PreparationsIBA 10/2020 - 03/2004
12	treprostinil FDA Link 03/2017 - 01/2006
11	NADPH Oxidases (NAD(P)H oxidase)IBA 07/2020 - 05/2004
11	EmulsionsIBA 06/2020 - 05/2002
11	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 09/2002
11	Messenger RNA (mRNA)IBA 01/2019 - 03/2002
11	Epoprostenol (Prostacyclin)FDA LinkGeneric 10/2011 - 04/2002
10	SmokeIBA 01/2022 - 10/2011
10	Small Interfering RNA (siRNA)IBA 12/2021 - 05/2005
9	EnzymesIBA 01/2022 - 01/2008
9	Semaxinib (SU5416)IBA 01/2022 - 09/2008
9	Superoxides (Superoxide)IBA 01/2020 - 12/2003
9	Soluble Guanylyl CyclaseIBA 01/2018 - 01/2006
9	AerosolsIBA 04/2017 - 12/2003
9	Fish OilsIBA 05/2015 - 05/2002
9	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2015 - 11/2002
8	Adenosine Triphosphatases (ATPase)IBA 12/2021 - 10/2005
8	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 09/2009
8	LipopolysaccharidesIBA 06/2018 - 06/2002
8	Phosphodiesterase 5 InhibitorsIBA 01/2018 - 01/2004
8	ThromboxanesIBA 02/2011 - 05/2002
7	Vasodilator Agents (Vasodilators)IBA 09/2021 - 01/2002
7	Pulmonary Surfactants (Pulmonary Surfactant)IBA 01/2021 - 01/2004
7	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 12/2003
7	Arachidonic Acid (Vitamin F)IBA 01/2018 - 05/2002
7	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidIBA 02/2011 - 12/2003
6	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 04/2011
6	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 02/2007
6	pirfenidoneIBA 11/2020 - 01/2015
6	Protein Isoforms (Isoforms)IBA 11/2020 - 04/2006
6	Fatty Acids (Saturated Fatty Acids)IBA 06/2020 - 05/2002
6	Omega-6 Fatty Acids (Omega 6 Fatty Acids)IBA 06/2020 - 05/2002
6	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2019 - 05/2002
6	LigandsIBA 01/2017 - 11/2007
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2014 - 06/2002
6	Imatinib Mesylate (Gleevec)FDA Link 01/2013 - 09/2005
6	Vasoconstrictor AgentsIBA 10/2007 - 05/2002
5	Histones (Histone)IBA 01/2021 - 07/2015
5	RNA (Ribonucleic Acid)IBA 11/2020 - 08/2017
5	AntioxidantsIBA 01/2019 - 01/2004
5	riociguatIBA 01/2019 - 03/2010
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2018 - 01/2002
5	FibrinIBA 12/2008 - 07/2002

Therapy/Procedure

63	Therapeutics 01/2022 - 04/2002
7	Parenteral Nutrition 06/2020 - 05/2003
6	Lung Transplantation 04/2021 - 01/2004
5	Immunomodulation 06/2020 - 02/2007
5	Lasers (Laser) 10/2015 - 09/2005